Developer docs
API playgroundTry for free, no card

Search company profiles

Meditip

Full company profile

uuid00039as

Namestring
Meditip
Legal namestring
주식회사 메디팁
Websiteurl
meditip.co.kr
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Meditip is a South Korea-based regulatory affairs (RA) consulting firm founded in 2007 that provides licensing and approval support for pharmaceuticals, biologics, medical devices, in vitro diagnostics (IVDs), health functional foods, and combination products across Korea, the United States, Europe, Japan, China, and Southeast Asia. The company's core service platform spans domestic and international regulatory approval consulting, insurance/reimbursement strategy, clinical development support, global market entry services, R&D commercialization, and CDMO (Contract Development and Manufacturing Organization) management consulting. Meditip also operates as a domestic representative for foreign companies seeking Korean market entry and, following the August 2024 acquisition of LSK SMO for 45 billion KRW, provides clinical trial site management organization (SMO) services.

Meditip generates revenue primarily through project-based and retainer-style professional services fees across five service lines: regulatory affairs consulting, clinical development, CDMO management, health functional food consulting, and SMO services. Since 2014, the company has completed more than 911 pharmaceutical and over 1,000 medical device regulatory projects, with reported revenue of 88 billion KRW in 2022 and management guidance of 150+ billion KRW for 2023. The company maintains an operating profit margin consistently above 15-20% annually. Go-to-market relies on direct B2B sales supported by a paid newsletter (75+ issues), annual symposiums drawing 200+ industry attendees, the Medtech School educational program for medical device startups, and integration within the DreamCIS/Tigermed ecosystem, which extends its effective reach to 62 countries.

Following the 2022 acquisition by DreamCIS (itself majority-owned by Chinese global CRO Tigermed), Meditip sits within an integrated drug development platform alongside DreamCIS (clinical) and LCS (non-clinical). The company raised 140 billion KRW in H2 2024 from Temasek, Highlight Capital, JL Partners, Sprouts International Holdings, and JC Asset Management, valuing it at 520 billion KRW post-money. Meditip is preparing for a KOSDAQ IPO targeted for H2 2026, which would make it the first publicly listed RA consulting company in Korea. Park Yang-soo was appointed CEO in April 2025, succeeding founder Yoo Jung-hee who transitioned to DreamCIS group-level strategy.

Short descriptiontext

Meditip is a South Korea-based regulatory affairs consulting firm providing licensing, clinical development, and global market entry services for pharmaceutical, medical device, IVD, and health functional food companies across Korea, the US, Europe, Japan, and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, healthcare licensing services, pharmaceutical regulatory approval, medical device certification, clinical development consulting
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Health Services8000
Product category
Healthcare Regulatory Affairs Consulting
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Regulatory Affairs (RA) Consulting Services
TypeProfessional Services
Description

Meditip provides professional consulting services for regulatory approvals of pharmaceuticals, medical devices, IVDs, health functional foods, and cosmetics. Revenue is generated on a project-by-project basis, typically structured as one-time fees per engagement or retainer-based contracts for ongoing regulatory support.

meditip.co.kr:443
2Clinical Development Consulting
TypeProfessional Services
Description

Clinical protocol design, IND/NDA/BLA submission support, clinical trial operation management, vendor matching, and post-marketing surveillance services. Revenue streams are project-based consulting fees.

meditip.co.kr:443
3CDMO Management Services
TypeProfessional Services
Description

CMC and CDMO management consulting for biopharmaceutical development, including production strategy design, partner selection, and quality/regulatory compliance management. Revenue is project-based consulting or retainer arrangements.

meditip.co.kr:443
4Health Functional Food Consulting
TypeProfessional Services
Description

Functional ingredient development, individual recognition type approval, labeling/advertising review, product registration, and import consulting for health functional foods.

meditip.co.kr:443
5SMO (Site Management Organization) Services
TypeProfessional Services
Description

Following the acquisition of LSK SMO's business rights (45 billion KRW), Meditip operates an SMO providing clinical trial site management, CRC deployment, and on-site clinical trial support services. Revenue is generated through service fees per clinical trial.

meditip.co.kr:443
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Custom project-based pricing for regulatory consulting engagements
ModelOtherBilling cadenceOther
Notes

No public price list available; inquiries are handled via dedicated phone lines for pharmaceutical and medical device consultations.

meditip.co.kr:443
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Meditip is a healthcare regulatory affairs (RA) and clinical development consulting firm that guides Korean and global biotech, pharmaceutical, and medical device companies through complex regulatory approval processes across Korea, USA, Europe, Japan, China, and Southeast Asia. The company provides licensing consulting for drugs, biologics, medical devices, IVDs, health functional foods, and combination products, along with clinical development, CMC/CDMO management, global market entry support, insurance/pricing strategy, and domestic representative services for foreign firms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 1,000 medical device projects and 911 regulatory approval projects completed since 2014
+3 more records
Product overview1 text field

Meditip is a comprehensive Healthcare regulatory approval and clinical development consulting company offering a full-cycle service platform. The company provides integrated regulatory consulting services across pharmaceuticals, medical devices, convergence products, and health functional foods. Core services include regulatory approval (인허가), insurance/pricing strategy, clinical development, global market research and entry, R&D support, and CDMO operation consulting. The company operates through partnerships with global regulatory bodies and has 29 overseas offices. Meditip is a subsidiary of DreamCIS (Tigermed group) and is preparing for IPO as the first RA consulting company in Korea to pursue listing.

Product and service1 record
1Pharmaceutical Regulatory Approval (인허가) Services
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

MOU for joint cooperation in human application testing for health functional foods. Global Medical Research Center conducts clinical and non-clinical research including human application tests for functional ingredient approvals. Meditip leverages this partnership to provide comprehensive one-stop services for health functional food development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Meditip acquired Promedicis through a merger and acquisition, expanding into the aesthetic/esthetic segment and strengthening its CRO capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Non-clinical consulting company within the DreamCIS group. Together with Meditip (RA) and DreamCIS (clinical), LCS completes the end-to-end drug development platform providing A-to-Z services from preclinical through commercialization.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Japanese SMO company participating in the Korea-China-Japan SMO cooperation workshop organized by DreamCIS and Meditip. Part of the broader Tigermed group's SMO network spanning Korea, Japan, and China.

5LSK SMO
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Meditip acquired LSK SMO's entire business rights for 45 billion KRW in August 2024, enabling Meditip to enter the SMO (Site Management Organization) market. LSK SMO was established in 2016 as a subsidiary of LSK Global Pharma Service and was Korea's #1 SMO. This acquisition marks Meditip's entry into clinical trial site management services.

meditip.co.kr
6Newrazin (뉴라진)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Partnership for full-cycle development of treatments for hereditary muscular diseases. Meditip provides regulatory affairs and clinical development support for Newrazin's pipeline.

meditip.co.kr
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

MOU signed for mutual cooperation in pharmaceutical development, leveraging complementary capabilities in development and regulatory affairs.

8Dongun Anatech (동운아나텍)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

MOU for medical device clinical and regulatory affairs cooperation for Dongun Anatech's D-SaLife saliva-based blood glucose measurement device. Meditip and DreamCIS support global regulatory strategy and clinical development for the device targeting China and India markets first.

meditip.co.kr
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Trilateral business agreement between the Association, DreamCIS, Meditip, and BX Plant (CDRO) for full-cycle new drug development support services for member companies, including R&D, non-clinical, regulatory affairs, clinical trials, business development, and investment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Meditip is a subsidiary of DreamCIS (acquired in 2022), which in turn is majority-owned by Chinese global CRO Tigermed. Meditip provides regulatory affairs (RA) services while DreamCIS provides clinical trial services, creating an integrated end-to-end drug development platform. The two companies jointly organize industry symposiums, share global networks, and cross-refer clients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tigermed is the parent company of DreamCIS, making Meditip part of the Tigermed group ecosystem. Tigermed operates in 62 countries with 10,000+ employees globally. The partnership enables Meditip to leverage Tigermed's global clinical trial infrastructure, regulatory networks, and multi-country market access capabilities for Korean biotech clients seeking to enter international markets.

12TGG (USA)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

US-based regulatory partner providing support for FDA regulatory approvals and US market entry services for Korean pharmaceutical and medical device products.

meditip.co.kr:443
Strategic tierMinorTypeStrategic or Co-development Partner
Description

European regulatory partner supporting EMA/CE regulatory approvals and European market entry for Korean healthcare products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Japanese regulatory and CRO partner supporting PMDA approvals and Japanese market entry for Korean pharmaceutical and medical device companies.

15Beijing Regitrans (China)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Chinese regulatory partner supporting NMPA/CFDA approvals and Chinese market entry for Korean pharmaceutical and medical device companies.

meditip.co.kr:443
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean clinical CRO that previously owned LSK SMO (acquired by Meditip for 45B KRW). Operates as a direct Korean CRO competitor across clinical development and has overlapping customer base in Korean biotech.

TypeDirect peer
Description

Korean CRO providing clinical trial services to biotech and pharmaceutical companies in Korea. Comparable Korean mid-market CRO serving similar pharmaceutical and medical device customer base.

TypeDirect peer
Description

Japan's largest CRO and Meditip's regulatory partner for PMDA approvals. Provides full-service clinical development, regulatory affairs, and CDMO services across Asia, making it the closest Asian geographic comparable.

TypeDirect peer
Description

Korean CRO providing clinical trial services. Mentioned in Meditip executive Kim Seon-a's background, indicating overlapping talent pool and customer base in Korean clinical research.

TypeBroad incumbent
Description

Chinese global CRO that owns DreamCIS (Meditip's parent). Operates in 62 countries with 10,000+ employees, offering clinical, regulatory, and bioanalytical services. Comparable global CRO serving similar biotech customers.

TypeBroad incumbent
Description

Global CRO and life sciences services leader offering clinical, regulatory, and commercial services worldwide. Larger-scale incumbent operating in same regulatory consulting category as Meditip but as part of broader portfolio.

TypeBroad incumbent
Description

China-headquartered global CRO/CDMO offering drug discovery, clinical, and regulatory services. Asian-headquartered incumbent with comparable biotech customer base across China and Korea.

TypeBroad incumbent
Description

Global CRO with strong regulatory affairs consulting capabilities across FDA, EMA, and APAC markets. Direct overlap with Meditip's regulatory consulting offering as part of broader clinical CRO portfolio.

TypeBroad incumbent
Description

Global biopharmaceutical services organization providing clinical development and regulatory consulting. Broader CRO with overlapping regulatory affairs service offerings to pharma and biotech.

TypeBroad incumbent
Description

Global CRO providing preclinical, clinical, and manufacturing services to biopharma. Larger established player with comparable regulatory and development consulting offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Meditip

Healthcare Regulatory Affairs Consultingmeditip.co.kr

Meditip is a South Korea-based regulatory affairs consulting firm providing licensing, clinical development, and global market entry services for pharmaceutical, medical device, IVD, and health functional food companies across Korea, the US, Europe, Japan, and China.

What Meditip does

Meditip is a South Korea-based regulatory affairs (RA) consulting firm founded in 2007 that provides licensing and approval support for pharmaceuticals, biologics, medical devices, in vitro diagnostics (IVDs), health functional foods, and combination products across Korea, the United States, Europe, Japan, China, and Southeast Asia. The company's core service platform spans domestic and international regulatory approval consulting, insurance/reimbursement strategy, clinical development support, global market entry services, R&D commercialization, and CDMO (Contract Development and Manufacturing Organization) management consulting. Meditip also operates as a domestic representative for foreign companies seeking Korean market entry and, following the August 2024 acquisition of LSK SMO for 45 billion KRW, provides clinical trial site management organization (SMO) services.

Meditip generates revenue primarily through project-based and retainer-style professional services fees across five service lines: regulatory affairs consulting, clinical development, CDMO management, health functional food consulting, and SMO services. Since 2014, the company has completed more than 911 pharmaceutical and over 1,000 medical device regulatory projects, with reported revenue of 88 billion KRW in 2022 and management guidance of 150+ billion KRW for 2023. The company maintains an operating profit margin consistently above 15-20% annually. Go-to-market relies on direct B2B sales supported by a paid newsletter (75+ issues), annual symposiums drawing 200+ industry attendees, the Medtech School educational program for medical device startups, and integration within the DreamCIS/Tigermed ecosystem, which extends its effective reach to 62 countries.

Following the 2022 acquisition by DreamCIS (itself majority-owned by Chinese global CRO Tigermed), Meditip sits within an integrated drug development platform alongside DreamCIS (clinical) and LCS (non-clinical). The company raised 140 billion KRW in H2 2024 from Temasek, Highlight Capital, JL Partners, Sprouts International Holdings, and JC Asset Management, valuing it at 520 billion KRW post-money. Meditip is preparing for a KOSDAQ IPO targeted for H2 2026, which would make it the first publicly listed RA consulting company in Korea. Park Yang-soo was appointed CEO in April 2025, succeeding founder Yoo Jung-hee who transitioned to DreamCIS group-level strategy.

Meditip firmographics

Firmographics
Name
Meditip
Legal name
주식회사 메디팁
Website
https://meditip.co.kr
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Meditip is a South Korea-based regulatory affairs consulting firm providing licensing, clinical development, and global market entry services for pharmaceutical, medical device, IVD, and health functional food companies across Korea, the US, Europe, Japan, and China.
Ownership category
akta.pro rank

Meditip industry classification

Industry
Product category
Healthcare Regulatory Affairs Consulting
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Regulatory affairs consulting
  • Healthcare licensing services
  • Pharmaceutical regulatory approval
  • Medical device certification
  • Clinical development consulting

Where Meditip is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Meditip business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Regulatory Affairs (RA) Consulting Services: Meditip provides professional consulting services for regulatory approvals of pharmaceuticals, medical devices, IVDs, health functional foods, and cosmetics. Revenue is generated on a project-by-project basis, typically structured as one-time fees per engagement or retainer-based contracts for ongoing regulatory support.
  2. Clinical Development Consulting: Clinical protocol design, IND/NDA/BLA submission support, clinical trial operation management, vendor matching, and post-marketing surveillance services. Revenue streams are project-based consulting fees.
  3. CDMO Management Services: CMC and CDMO management consulting for biopharmaceutical development, including production strategy design, partner selection, and quality/regulatory compliance management. Revenue is project-based consulting or retainer arrangements.
  4. Health Functional Food Consulting: Functional ingredient development, individual recognition type approval, labeling/advertising review, product registration, and import consulting for health functional foods.
  5. SMO (Site Management Organization) Services: Following the acquisition of LSK SMO's business rights (45 billion KRW), Meditip operates an SMO providing clinical trial site management, CRC deployment, and on-site clinical trial support services. Revenue is generated through service fees per clinical trial.

Pricing tiers

ModelBillingPrice
OtherOtherCustom project-based pricing for regulatory consulting engagements

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Meditip product offering

Product offering

Core offering

Meditip is a healthcare regulatory affairs (RA) and clinical development consulting firm that guides Korean and global biotech, pharmaceutical, and medical device companies through complex regulatory approval processes across Korea, USA, Europe, Japan, China, and Southeast Asia. The company provides licensing consulting for drugs, biologics, medical devices, IVDs, health functional foods, and combination products, along with clinical development, CMC/CDMO management, global market entry support, insurance/pricing strategy, and domestic representative services for foreign firms.

Product overview

Meditip is a comprehensive Healthcare regulatory approval and clinical development consulting company offering a full-cycle service platform. The company provides integrated regulatory consulting services across pharmaceuticals, medical devices, convergence products, and health functional foods. Core services include regulatory approval (인허가), insurance/pricing strategy, clinical development, global market research and entry, R&D support, and CDMO operation consulting. The company operates through partnerships with global regulatory bodies and has 29 overseas offices. Meditip is a subsidiary of DreamCIS (Tigermed group) and is preparing for IPO as the first RA consulting company in Korea to pursue listing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Regulatory Approval (인허가) Services

Quantifiable outcome

  • Over 1,000 medical device projects and 911 regulatory approval projects completed since 2014
  • +3 more outcomes

Companies that use Meditip

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Meditip technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Meditip partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered minor and core.

  • Global Medical Research Center (글로벌의학연구센터)minorStrategic or Co-development Partner · 1 September 2025MOU for joint cooperation in human application testing for health functional foods. Global Medical Research Center conducts clinical and non-clinical research including human application tests for functional ingredient approvals. Meditip leverages this partnership to provide comprehensive one-stop services for health functional food development.
  • PromedicisminorStrategic or Co-development Partner · 1 January 2025Meditip acquired Promedicis through a merger and acquisition, expanding into the aesthetic/esthetic segment and strengthening its CRO capabilities.
  • LCS (비엑스플랜트)coreStrategic or Co-development Partner · 1 December 2024Non-clinical consulting company within the DreamCIS group. Together with Meditip (RA) and DreamCIS (clinical), LCS completes the end-to-end drug development platform providing A-to-Z services from preclinical through commercialization.
  • Accerise (Japan)minorStrategic or Co-development Partner · 1 October 2024Japanese SMO company participating in the Korea-China-Japan SMO cooperation workshop organized by DreamCIS and Meditip. Part of the broader Tigermed group's SMO network spanning Korea, Japan, and China.
  • LSK SMOcoreStrategic or Co-development Partner · 1 August 2024Meditip acquired LSK SMO's entire business rights for 45 billion KRW in August 2024, enabling Meditip to enter the SMO (Site Management Organization) market. LSK SMO was established in 2016 as a subsidiary of LSK Global Pharma Service and was Korea's #1 SMO. This acquisition marks Meditip's entry into clinical trial site management services.
  • Newrazin (뉴라진)minorStrategic or Co-development Partner · 1 August 2024Partnership for full-cycle development of treatments for hereditary muscular diseases. Meditip provides regulatory affairs and clinical development support for Newrazin's pipeline.
  • Cosmaxpharma (코스맥스파마)minorStrategic or Co-development Partner · 1 June 2024MOU signed for mutual cooperation in pharmaceutical development, leveraging complementary capabilities in development and regulatory affairs.
  • Dongun Anatech (동운아나텍)minorStrategic or Co-development Partner · 1 March 2024MOU for medical device clinical and regulatory affairs cooperation for Dongun Anatech's D-SaLife saliva-based blood glucose measurement device. Meditip and DreamCIS support global regulatory strategy and clinical development for the device targeting China and India markets first.
  • Korean New Drug Development Research Association (신약개발연구조합)minorStrategic or Co-development Partner · 1 March 2024Trilateral business agreement between the Association, DreamCIS, Meditip, and BX Plant (CDRO) for full-cycle new drug development support services for member companies, including R&D, non-clinical, regulatory affairs, clinical trials, business development, and investment.
  • DreamCIS (드림씨아이에스)coreStrategic or Co-development PartnerMeditip is a subsidiary of DreamCIS (acquired in 2022), which in turn is majority-owned by Chinese global CRO Tigermed. Meditip provides regulatory affairs (RA) services while DreamCIS provides clinical trial services, creating an integrated end-to-end drug development platform. The two companies jointly organize industry symposiums, share global networks, and cross-refer clients.
  • Tigermed (타이거메드)coreStrategic or Co-development PartnerTigermed is the parent company of DreamCIS, making Meditip part of the Tigermed group ecosystem. Tigermed operates in 62 countries with 10,000+ employees globally. The partnership enables Meditip to leverage Tigermed's global clinical trial infrastructure, regulatory networks, and multi-country market access capabilities for Korean biotech clients seeking to enter international markets.
  • TGG (USA)minorStrategic or Co-development PartnerUS-based regulatory partner providing support for FDA regulatory approvals and US market entry services for Korean pharmaceutical and medical device products.
  • Woodley BioReg Ltd (Europe)minorStrategic or Co-development PartnerEuropean regulatory partner supporting EMA/CE regulatory approvals and European market entry for Korean healthcare products.
  • CMIC (Japan)minorStrategic or Co-development PartnerJapanese regulatory and CRO partner supporting PMDA approvals and Japanese market entry for Korean pharmaceutical and medical device companies.
  • Beijing Regitrans (China)minorStrategic or Co-development PartnerChinese regulatory partner supporting NMPA/CFDA approvals and Chinese market entry for Korean pharmaceutical and medical device companies.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Meditip competitors and assessment

Company assessment

Direct peers

  • LSK Global Pharma Service: Korean clinical CRO that previously owned LSK SMO (acquired by Meditip for 45B KRW). Operates as a direct Korean CRO competitor across clinical development and has overlapping customer base in Korean biotech.
  • Pharmaresearch: Korean CRO providing clinical trial services to biotech and pharmaceutical companies in Korea. Comparable Korean mid-market CRO serving similar pharmaceutical and medical device customer base.
  • CMIC Holdings: Japan's largest CRO and Meditip's regulatory partner for PMDA approvals. Provides full-service clinical development, regulatory affairs, and CDMO services across Asia, making it the closest Asian geographic comparable.
  • C&R Research: Korean CRO providing clinical trial services. Mentioned in Meditip executive Kim Seon-a's background, indicating overlapping talent pool and customer base in Korean clinical research.

Broad incumbents

  • Tigermed: Chinese global CRO that owns DreamCIS (Meditip's parent). Operates in 62 countries with 10,000+ employees, offering clinical, regulatory, and bioanalytical services. Comparable global CRO serving similar biotech customers.
  • IQVIA: Global CRO and life sciences services leader offering clinical, regulatory, and commercial services worldwide. Larger-scale incumbent operating in same regulatory consulting category as Meditip but as part of broader portfolio.
  • WuXi AppTec: China-headquartered global CRO/CDMO offering drug discovery, clinical, and regulatory services. Asian-headquartered incumbent with comparable biotech customer base across China and Korea.
  • Parexel International: Global CRO with strong regulatory affairs consulting capabilities across FDA, EMA, and APAC markets. Direct overlap with Meditip's regulatory consulting offering as part of broader clinical CRO portfolio.
  • Syneos Health: Global biopharmaceutical services organization providing clinical development and regulatory consulting. Broader CRO with overlapping regulatory affairs service offerings to pharma and biotech.
  • Charles River Laboratories: Global CRO providing preclinical, clinical, and manufacturing services to biopharma. Larger established player with comparable regulatory and development consulting offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Meditip social profiles

Digital presence

Meditip financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Meditip leadership team

Management profile

Number of profiles

Profiles5 records

Meditip subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Meditip funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Meditip M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meditip

What does Meditip do?

Meditip is a healthcare regulatory affairs (RA) and clinical development consulting firm that guides Korean and global biotech, pharmaceutical, and medical device companies through complex regulatory approval processes across Korea, USA, Europe, Japan, China, and Southeast Asia. The company provides licensing consulting for drugs, biologics, medical devices, IVDs, health functional foods, and combination products, along with clinical development, CMC/CDMO management, global market entry support, insurance/pricing strategy, and domestic representative services for foreign firms.

Is Meditip a public or private company?

Meditip is a private company. It is classified as corporate owned and is currently operating.

When was Meditip founded?

Meditip was founded in 2007. It employs 11 to 50 people.

Where is Meditip based?

Meditip is headquartered in Seoul, South Korea, in the Asia region.

How does Meditip make money?

Five revenue lines are on record. Regulatory Affairs (RA) Consulting Services are the primary driver. The others are clinical Development Consulting, CDMO Management Services, health Functional Food Consulting and SMO (Site Management Organization) Services.

Who are Meditip's main competitors?

Direct peers on record are LSK Global Pharma Service, Pharmaresearch, CMIC Holdings and C&R Research. Broad incumbents are Tigermed, IQVIA, WuXi AppTec, Parexel International, Syneos Health and Charles River Laboratories.

Does Meditip have an API?

No public API is recorded for Meditip.

What industry is Meditip in?

Meditip's product category is Healthcare Regulatory Affairs Consulting. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales